Last updated: 2026-09-04 12:57:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
iBio, Inc. (IBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,30, with a market capitalization of $84,24M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,77 to $3,82. This page covers its latest market performance, valuation, price trends and company information.
$84,24M | |
$1,30 | |
$30.300,00 | |
$0,56 | |
$1,30 | |
910,00 | |
-- | |
-- | |
$3,82 | |
$0,77 | |
-- | |
-- |
iBio, Inc. (IBIO) last closed at $1,30 as of 2026-09-04 12:50:00, unchanged from the previous close of $1,30.
During the latest regular trading session, IBIO traded between $0,56 and $30.300,00, with a volume of 910,00 shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, iBio, Inc. (IBIO) moved from $1,37 to $1,30, representing a decline of 4,89% ($0,07).
The stock traded between $1,21 and $1,46 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 667,66 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 17,5%
IBIO is currently trading at $1,30, placing it 17,5% of the way from its 52-week low of $0,77 to its 52-week high of $3,82. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 23 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of iBio, Inc. (IBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.